Brokerages expect that Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) will report sales of $31.32 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Tabula Rasa Healthcare’s earnings, with the lowest sales estimate coming in at $31.14 million and the highest estimate coming in at $31.50 million. Tabula Rasa Healthcare posted sales of $24.17 million in the same quarter last year, which suggests a positive year-over-year growth rate of 29.6%. The company is scheduled to announce its next quarterly earnings results after the market closes on Monday, November 6th.

According to Zacks, analysts expect that Tabula Rasa Healthcare will report full year sales of $31.32 million for the current year, with estimates ranging from $127.30 million to $128.00 million. For the next year, analysts anticipate that the firm will post sales of $177.62 million per share, with estimates ranging from $172.60 million to $180.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Tabula Rasa Healthcare.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its earnings results on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.06. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The business had revenue of $29.70 million for the quarter, compared to analyst estimates of $27.84 million. The company’s revenue was up 32.6% on a year-over-year basis.

A number of research analysts recently commented on TRHC shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $16.00 price target on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $29.00 price target (up previously from $20.00) on shares of Tabula Rasa Healthcare in a research note on Wednesday, September 20th. UBS AG boosted their price target on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 30th. Robert W. Baird boosted their price target on Tabula Rasa Healthcare from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Finally, Wells Fargo & Company boosted their target price on Tabula Rasa Healthcare from $21.00 to $27.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Tabula Rasa Healthcare currently has an average rating of “Buy” and an average price target of $27.50.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/31-32-million-in-sales-expected-for-tabula-rasa-healthcare-inc-trhc-this-quarter.html.

In other Tabula Rasa Healthcare news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $17.21, for a total transaction of $137,680.00. Following the completion of the transaction, the chief executive officer now owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 24,000 shares of company stock valued at $527,920. Insiders own 45.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Hood River Capital Management LLC grew its holdings in shares of Tabula Rasa Healthcare by 7.5% during the second quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after purchasing an additional 57,724 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Tabula Rasa Healthcare by 13.4% during the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after purchasing an additional 27,997 shares during the last quarter. Boston Partners grew its holdings in shares of Tabula Rasa Healthcare by 17.1% during the second quarter. Boston Partners now owns 235,180 shares of the company’s stock worth $3,540,000 after purchasing an additional 34,360 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Tabula Rasa Healthcare by 97.4% during the second quarter. Northern Trust Corp now owns 95,862 shares of the company’s stock worth $1,443,000 after purchasing an additional 47,306 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Tabula Rasa Healthcare by 58.1% during the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock worth $1,415,000 after purchasing an additional 34,565 shares during the last quarter. Institutional investors own 27.94% of the company’s stock.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Get a free copy of the Zacks research report on Tabula Rasa Healthcare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.